The Zhitong Finance App learned that Goldman Sachs released a research report, maintained Fu Hong Hanlin's (02696.HK) “buy” rating, and raised the 12-month target price from HK$104.79 to HK$112.01. In its report, Goldman Sachs analyzed the strategic cooperation reached between Fuhong Hanlin and Sandoz, a global generic drug and biosimilar company. As of Thursday's close, Fu Hong Hanlin (02696.HK) closed up 7.32% to HK$70.35. The stock has accumulated an increase of more than 23% this year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.